The sticker price of Wegovy can run north of $1,000 a month. Starting July 1, 2026, some Medicare beneficiaries can snag it for $50 a month. The catch is the qualifying list, which is narrower than the headlines suggest, and the exclusions that will surprise the people who assume they are first in line
The Centers for Medicare & Medicaid Services calls the new demonstration the Medicare GLP-1 Bridge. It is a temporary program, available nationwide, that runs alongside but outside Part D through December 31, 2027. Part D enrollment is required, but the drug does not need to appear on your plan’s formulary, and the plan does not have to opt in. If your BMI, health history, and prescription all line up, the copay is fixed at $50 per month for a covered GLP-1. If any one of those pieces is off, the bridge does nothing for you.
Who Actually Qualifies
Three covered drugs are on the list: Wegovy (injection or tablet), Zepbound (KwikPen only, not vials or single-dose pens), and Foundayo (tablet). You must be 18 or older and enrolled in an eligible Medicare drug plan. Those include standalone PDPs, most HMO and PPO MA-PD plans, Special Needs Plans, and employer or union group waiver plans. Certain private fee-for-service, cost, and PACE plans do not qualify unless the beneficiary also has an eligible standalone PDP. If you have Original Medicare and no Part D, the bridge is closed to you until you enroll in a plan.
Beyond that, eligibility hinges on BMI and comorbidity, and CMS drew the lines tightly. The measurements and diagnoses generally must have been present when GLP-1 therapy began:
- BMI of 35 or higher: qualifies on BMI alone.
- BMI of 30 or higher plus one of the following: heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease at stage 3a or higher. CMS defines uncontrolled hypertension as blood pressure above 140 systolic or 90 diastolic despite treatment with two blood-pressure medications.
- BMI of 27 or higher plus one of the following: prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease.
A doctor has to certify the diagnosis and submit prior authorization. The prescription must be for weight reduction or maintenance alongside ongoing nutrition and physical activity. A self-reported BMI and a vague complaint about blood pressure will not clear the gate
The Exclusions That Trip People Up
Here is the part most patients miss. The bridge does not apply if you received a GLP-1 through Part D during 2026 or are being prescribed one for an indication already eligible for Part D coverage, even if the drug is missing from your plan’s formulary. It explicitly excludes people with type 2 diabetes, moderate-to-severe obstructive sleep apnea, or noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate-to-advanced liver fibrosis. That is narrower than simply having “fatty liver disease.”
Those beneficiaries go back to their Part D plans, where cost-sharing depends on the drug’s tier, deductible, and formulary. That can be far more than $50, or the drug may require a formulary exception
The framing matters. A 68-year-old with type 2 diabetes and a BMI of 34 has an existing pathway to a GLP-1 through Part D. She is not eligible for the $50 bridge copay. A 68-year-old with prediabetes and a BMI of 28 may qualify if the prescription is for weight management
A prior heart attack creates an extra wrinkle. It can help satisfy the Bridge’s BMI-27 tier, but if Wegovy is prescribed to reduce cardiovascular risk, the claim belongs in Part D. The diagnosis may be the same. The purpose of the prescription changes the lane
How the $50 Copay Interacts With the Rest of Your Medicare Bill
The bridge sits outside Part D, so the $50 does not run through your Part D deductible or the annual out-of-pocket cap. You still pay your normal Part D premium and any Part D IRMAA surcharge you already owe. For 2026, that Part D surcharge runs from $14.50 a month at the first tier to $91.00 a month at the top, layered on top of your plan premium. The bridge does not change any of that
Extra Help does not reduce the $50 copay, and the payment cannot be spread through the Medicare Prescription Payment Plan. It also does not move you any closer to Part D’s $2,100 annual out-of-pocket limit. The Bridge is cheaper, but it keeps a separate tab
For a retiree whose Social Security check rose just 2.8% in 2026, $50 for a monthly supply is meaningful. Twelve fills cost $600 for a drug that can carry a five-figure annual sticker price. That is real relief, provided the paperwork agrees
What to Do
The Bridge has a low price and a narrow doorway. Three steps will tell you whether it is worth knocking
- Confirm your Part D enrollment and plan type. The bridge requires both. If you are on Original Medicare with no drug plan, you cannot access the $50 copay until you add one. The next Annual Enrollment Period runs October 15 to December 7, with new coverage generally beginning January 1.
- Ask your primary care doctor or cardiologist to pull your BMI at the time therapy began, qualifying diagnoses, and current treatment information onto one page and match them against the three eligibility tiers before requesting a prescription. If the authorization is denied because information was wrong or incomplete, the provider can resubmit it with corrections. The Bridge has no formal appeal process.
- If you have type 2 diabetes, moderate-to-severe obstructive sleep apnea, or qualifying MASH with liver fibrosis, skip the bridge and ask your Part D plan which GLP-1 is on its formulary, what tier it sits on, and how to request an exception if necessary. That is your actual coverage path.
This is not broad Medicare coverage for weight-loss drugs. It is a narrow bridge, but for the people who fit, $50 is worth finding
Program rules reflect the 2026 plan year and the Medicare GLP-1 Bridge as
Contact [email protected] for any questions or corrections
